Five-year survival with combined nivolumab and ipilimumab in advanced melanoma

J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, Christopher Lao, CL Cowey, D Schadendorf, J Wagstaff, R Dummer, PF Ferrucci, M Smylie, D Hogg, A Hill, I Márquez-Rodas, J Haanen, M Guidoboni, M Maio, P Schöffski, . Carlino, C Lebbé, G McArthur, PA Ascierto, GA Daniels, GV Long, L Bastholt, JI Rizzo, A Balogh, A Moshyk, FS Hodi, JD Wolchok

2019, New England Journal of Medicine - Article

Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy

I Tsung, R Dolan, Christopher Lao, Leslie Fecher, K Riggenbach, A Yeboah-Korang, Robert Fontana

2019, Alimentary Pharmacology and Therapeutics - Article

Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study (BMC Cancer. (2017) 17 (332) DOI: 10.1186/s12885-017-3286-5)

A Sekulic, . Migden, N Basset-Seguin, C Garbe, A Gesierich, Christopher Lao, C Miller, L Mortier, DF Murrell, O Hamid, JF Quevedo, J Hou, E McKenna, N Dimier, S Williams, D Schadendorf, A Hauschild

2019, BMC Cancer - Article

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

EI Buchbinder, JP Dutcher, GA Daniels, BD Curti, SP Patel, SG Holtan, GP Miletello, MN Fishman, R Gonzalez, JI Clark, JM Richart, Christopher Lao, SS Tykodi, AW Silk, DF McDermott

2019, Journal for ImmunoTherapy of Cancer - Article

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

FS Hodi, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CL Cowey, Christopher Lao, D Schadendorf, J Wagstaff, R Dummer, PF Ferrucci, M Smylie, A Hill, D Hogg, I Marquez-Rodas, J Jiang, J Rizzo, J Larkin, JD Wolchok

2018, The Lancet Oncology - Article

Combined nivolumab and ipilimumab in melanoma metastatic to the brain

HA Tawbi, PA Forsyth, A Algazi, O Hamid, FS Hodi, SJ Moschos, NI Khushalani, K Lewis, Christopher Lao, MA Postow, MB Atkins, . Ernstoff, DA Reardon, I Puzanov, RR Kudchadkar, RP Thomas, A Tarhini, AC Pavlick, J Jiang, A Avila, S Demelo, K Margolin

2018, New England Journal of Medicine - Article

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

JI Clark, J Singh, . Ernstoff, Christopher Lao, LE Flaherty, TF Logan, B Curti, SS Agarwala, B Taback, L Cranmer, J Lutzky, TL Luna, S Aung, DH Lawson

2018, Journal for ImmunoTherapy of Cancer - Article

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression

H Lin, Shuang Wei, EM Hurt, Michael Green, L Zhao, L Vatan, W Szeliga, R Herbst, Paul Harms, Leslie Fecher, P Vats, Arul Chinnaiyan, Christopher Lao, Theodore Lawrence, Max Wicha, J Hamanishi, M Mandai, Ilona Kryczek, W Zou, Lili Zhao

2018, The Journal of clinical investigation - Article

Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

J Larkin, D Minor, S D'Angelo, B Neyns, M Smylie, WH Miller, R Gutzmer, G Linette, B Chmielowski, Christopher Lao, P Lorigan, K Grossmann, JC Hassel, M Sznol, A Daud, J Sosman, N Khushalani, D Schadendorf, C Hoeller, D Walker, G Kong, C Horak, J Weber

2018, Journal of Clinical Oncology - Article

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

H Lin, Shuang Wei, EM Hurt, Michael Green, Lili Zhao, L Vatan, W Szeliga, R Herbst, Paul Harms, Leslie Fecher, P Vats, Arul Chinnaiyan, Christopher Lao, Theodore Lawrence, Max Wicha, J Hamanishi, M Mandai, Ilona Kryczek, Weiping Zou, Qiao Li

2018, Journal of Clinical Investigation - Article

Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: A pooled analysis of randomized phase II and III trials

D Schadendorf, JD Wolchok, F Stephen Hodi, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, C Lance Cowey, Christopher Lao, J Chesney, C Robert, K Grossmann, D McDermott, D Walker, R Bhore, J Larkin, MA Postow

2017, Journal of Clinical Oncology - Article

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, CL Cowey, Christopher Lao, J Wagstaff, D Schadendorf, PF Ferrucci, M Smylie, R Dummer, A Hill, D Hogg, J Haanen, . Carlino, O Bechter, M Maio, I Marquez-Rodas, M Guidoboni, G McArthur, C Lebbé, PA Ascierto, GV Long, J Cebon, J Sosman, MA Postow, MK Callahan, D Walker, L Rollin, R Bhore, FS Hodi, J Larkin

2017, New England Journal of Medicine - Article

Health-related quality of life results from the phase III CheckMate 067 study

D Schadendorf, J Larkin, J Wolchok, FS Hodi, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, CL Cowey, Christopher Lao, J Wagstaff, MK Callahan, MA Postow, M Smylie, PF Ferrucci, R Dummer, A Hill, F Taylor, J Sabater, D Walker, S Kotapati, A Abernethy, GV Long

2017, European Journal of Cancer - Article

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607)

K Kalinsky, S Lee, KM Rubin, DP Lawrence, AJ Iafrarte, . Borger, KA Margolin, MM Leitao, AA Tarhini, HB Koon, AL Pecora, AJ Jaslowski, GI Cohen, TM Kuzel, Christopher Lao, JM Kirkwood

2017, Cancer - Article

Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis

J Larkin, B Chmielowski, Christopher Lao, FS Hodi, W Sharfman, J Weber, KPM Suijkerbuijk, S Azevedo, H Li, D Reshef, A Avila, DA Reardon

2017, Oncologist - Article

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study

A Sekulic, . Migden, N Basset-Seguin, C Garbe, A Gesierich, Christopher Lao, C Miller, L Mortier, DF Murrell, O Hamid, JF Quevedo, J Hou, E McKenna, N Dimier, S Williams, D Schadendorf, A Hauschild

2017, BMC Cancer - Article

Erratum to: Metastatic Merkel cell carcinoma response to nivolumab. [J Immunother Cancer. 4, (2016), (79)] DOI: 10.1186/s40425-016-0186-1.

FM Walocko, BY Scheier, Paul Harms, Leslie Fecher, Christopher Lao

2017, Journal for ImmunoTherapy of Cancer - Article

Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma

TM Atkinson, JL Hay, A Shoushtari, Y Li, DJ Paucar, SC Smith, RR Kudchadkar, A Doyle, JA Sosman, JF Quevedo, MM Milhem, AM Joshua, GP Linette, TF Gajewski, J Lutzky, DH Lawson, Christopher Lao, PJ Flynn, . Albertini, T Sato, K Lewis, B Marr, DH Abramson, MA Dickson, GK Schwartz, RD Carvajal

2017, Journal of Cancer Research and Clinical Oncology - Article

Metastatic Merkel cell carcinoma response to nivolumab

FM Walocko, BY Scheier, Paul Harms, Leslie Fecher, Christopher Lao

2016, Journal for ImmunoTherapy of Cancer - Article

Management of adverse events following treatment with anti-programmed death-1 agents

JS Weber, M Postow, Christopher Lao, D Schadendorf

2016, Oncologist - Article

Load more…